// App-Quantinova.ai

3095.0 : Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.

Researchers

Presenter

  • Taiki Hakozaki

Principal Investigators

  • Corentin Richard

  • Yusuke Okuma

  • Lisa Derosa

  • Arielle Elkrief

  • Laurence Zitvogel

  • Bertrand Routy

  • Yukio Hosomi

Medical Centers

  • Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan

  • Centre de Recherche du Centre Hospitalier de lUniversite de Montreal, Montreal, QC, Canada

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

  • U1015 INSERM, Gustave Roussy Cancer Campus, Paris Saclay University, Villejuif, France

  • McGill University Health Centre, Montreal, QC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

Locations

  • Japan

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved